EpiCast Report: Painful Diabetic Neuropathy - Epidemiology Forecast to 2026

  • ID: 4465621
  • Drug Pipelines
  • 40 pages
  • GlobalData
1 of 3
EpiCast Report: Painful Diabetic Neuropathy - Epidemiology Forecast to 2026

Summary

Diabetic neuropathy is a long-term complication of diabetes mellitus (DM). Diabetic patients may, over time, develop this nerve disorder, as it is the result of decreased blood flow and high blood sugar levels (Sadosky et al., 2008). Diabetic neuropathy involves a variety of syndromes that differ in clinical course, distribution, and fiber involvement. Painful diabetic neuropathy (PDN) is a subtype of diabetic neuropathy where patients experience painful symptoms as a result of nerve damage.

PDN is often diagnosed by determining the location and intensity of neuropathic pain by using validated questionnaires such as the Brief Pain Inventory (BPI) or the Michigan Neuropathy Screening Instrument (MNSI). Diagnosis of PDN also involves a sensory examination. During sensory examinations, touch is assessed by applying cotton wool to the skin, determining pinprick sensation, determining thermal sensation by the application of cold and warm objects, and determining vibration sensation by the application of a 128-Hz turning fork (IASP, 2015). According to the IASP, PDN is a cause of considerable morbidity, and studies on the quality of life of PDN patients show that the disorder has a substantial negative impact in many areas such as mood and ability to maintain work (IASP, 2015).

In the 7MM, the total prevalent cases of painful diabetic neuropathy in the diagnosed diabetic population is expected to increase from approximately 7.8 million total prevalent cases in 2016 to about 10.8 million cases in 2026. The diagnosed prevalent cases of PDN are expected to grow from 4.7 million diagnosed prevalent cases in 2016 to 7.1 million cases in 2026.

The report "EpiCast Report: Painful Diabetic Neuropathy - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and global and historical trends for diabetic patients who experience PDN in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for total prevalent cases of PDN (diagnosed and undiagnosed) among the diagnosed diabetic population segmented by sex and age (beginning at age 18 years and ending at ages 85 years and older) in these markets. The total prevalent cases of PDN are further segmented into mild, moderate, and severe neuropathy, and typical or atypical PDN. This report also provides a forecast for the diagnosed prevalent cases of PDN.

Scope
  • The Painful Diabetic Neuropathy (PDN) EpiCast Report provides an overview of the risk factors and global trends of PDN in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • It includes a 10-year epidemiological forecast for total prevalent cases of PDN (diagnosed and undiagnosed) among the diagnosed diabetic population segmented by sex and age (beginning at age 18 years and ending at ages 85 years and older) in these markets. The total prevalent cases of PDN are further segmented into mild, moderate, and severe neuropathy, and typical or atypical PDN. This report also provides a forecast for the diagnosed prevalent cases of PDN.
  • The PDN epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The PDN EpiCast report will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global PDN market.
  • Quantify patient populations in the global PDN market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PDN therapeutics in each of the markets covered.
  • Understand magnitude of PDN population by severity, as well as typical or atypical PDN.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents

2 Painful Diabetic Neuropathy: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for PDN (2016-2026)
3.5.1 Total Prevalent Cases of PDN
3.5.2 Age-Specific Total Prevalent Cases of PDN
3.5.3 Sex-Specific Total Prevalent Cases of PDN
3.5.4 Total Prevalent Cases of PDN by Severity of Neuropathy
3.5.5 Total Prevalent Cases of Typical and Atypical PDN
3.5.6 Diagnosed Prevalent Cases of PDN
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About
4.5 Contact
4.6 Disclaimer

List of Tables
Table 1: Risk Factors, and Comorbidities for PDN
Table 2: Total Prevalent Cases of PDN, Men and Women, Ages =18 Years, Select Years 2016-2026
Table 3: Diagnosed Prevalent Cases of PDN, Men and Women, Ages =18 Years, Select Years 2016-2026
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: 7MM, Total Prevalent Cases of PDN, Both Sexes, Ages =18 Years, 2016 and 2026
Figure 2: 7MM, Diagnosed Prevalent Cases of PDN, Both Sexes, Ages =18 Years, 2016 and 2026
Figure 3 Case Flow Map
Figure 4: Sources Used and Not Used for Diagnosed Prevalent Cases of T2D Among the General Population
Figure 5: Sources Used for Diagnosed Prevalent Cases of T1D Among the General Population
Figure 6: Sources Used for Total Prevalent Cases of PDN Among the Diagnosed Diabetic Population
Figure 7: Sources Used for Total Prevalent Cases of PDN by Severity of Neuropathy
Figure 8: Sources Used for Total Prevalent Cases of Typical and Atypical PDN
Figure 9: Sources Used for Diagnosed Prevalent Cases of PDN
Figure 10: 7MM, Age-Specific Total Prevalent Cases of PDN, Men and Women, Ages =18 Years, 2016
Figure 11: 7MM, Sex-Specific Total Prevalent Cases of PDN, Men, Women, Ages =18 Years, 2016
Figure 12: 7MM, Total Prevalent Cases of PDN by Severity of Neuropathy, Men and Women, Ages =18 Years, 2016.
Figure 13: 7MM, Total Prevalent Cases of Typical and Atypical PDN, Men and Women, Ages =18 Years, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll